How pay-for-delay affects competition and innovation in the pharmaceutical industry

• Xuelin Li
• Richard Thakor

Fishy business in an expert product review

• Ben Vollaard
• Jan C. van Ours

Privacy & Antitrust: "Integration", not just "Intersection"

Privacy & Antitrust: "Integration", not just "Intersection": Panel 1 - What are the Privacy Experts Seeing that the Antitrust Regulators are not?

Privacy & Antitrust: "Integration", not just "Intersection": Panel 2 - What's the Progress on Integrating Antitrust & Privacy?

Privacy and antitrust: 'Integration', not just 'intersection'

• Cristina Caffarra
• Gregory Crawford interviewed by
• Tim Phillips

Turning competition research into competition policy

• Cristina Caffarra
• Gregory Crawford interviewed by
• Tim Phillips

The CEPR's Research Policy Network on competition policy launches this week. In the first of two special podcasts on the topic, Greg Crawford and Cristina Caffarra tell Tim Phillips why it is so important to have this debate now, and how academics can use the RPN to connect their research to real-world policy.

Individualised pricing can abate market power and mitigate merger effects

• Howard Smith
• Yuya Takahashi
• Walter Beckert

The antitrust orthodoxy is blind to real data harms

• Gregory Crawford
• Johnny Ryan
• Cristina Caffarra

Why I agree with the Google-Fitbit decision

• Pierre Régibeau

Antitrust markets in the pharmaceutical industry: A logical definition

• Carmine Ornaghi
• Georges Siotis
• Micael Castanheira

Pooled procurement of drugs in low- and middle-income countries can lower prices and improve access

• Yassine Lefouili
• Stephane Straub
• Pierre Dubois